Pharmacogenomics of proton pump inhibitors

Pharmacogenomics

Volumn 5, Issue 2, 2004, Pages 181-202

  Furuta, Takahisa ^a   Shirai, Naohito ^a   Sugimoto, Mitsushige ^a   Ohashi, Kyoichi ^a   Ishizaki, Takashi ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

CYP3A4; GERD; Helicobacter pylori; KYP2C19; Lansoprazole; NAB; Omeprazole; Rabeprazole

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CLARITHROMYCIN; CYANOCOBALAMIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LANSOPRAZOLE; LIVER ENZYME; MEPHENYTOIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CARCINOID; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; GASTROESOPHAGEAL REFLUX; GENETIC DIFFERENCE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIVER METABOLISM; MEDICAL DECISION MAKING; METABOLIC PARAMETERS; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; REVIEW; STOMACH PH; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTON PUMPS;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 1542394539     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.2.181.27483     Document Type: Review

References (105)

1. + ATPase. Ann. Rev. Pharmacol. Toxicol. 35, 277-305 (1995).
2. Blum RA: Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am. J Health Syst. Pharm. 53(12), 1401-1415 (1996).
3. Lockhart SP: Clinical review of lansoprazole. Br. J. Clin. Pract. Suppl. 75, 48-55; discussion 56-57 (1994).
4. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 54(3), 473-500 (1997).
5. Inatomi N, Nagaya H, Takami K, Shino A, Satoh H: Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn. J. Pharmacol. 55(4), 437-451 (1991).
6. CarswelA CI, Goa KL: Rabeprazole: an update of its use in acid-related disorders. Drugs 61(15), 2327-2356 (2001).
7. Unge P: Review of Helicobacter pylori eradication regimens. Scand. J. Gastroenterol. Suppl. 215, 74-81 (1996).
8. Asaka M, Sugiyama T, Kato M et al.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6(3), 254-261 (2001).
9. Furuta T, Futami H, Arai H, Hanai H, Kaneko E: Effects of lansoprazole with or without amoxicillin on ulcer healing: Relation to eradication of Helicobacter pylori. J. Clin. Gastroenterol. 20(Suppl. 2), S107-111 (1995).
10. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L: Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12(4), 415-416 (1990).
11. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2(1), 25-31 (1992).
12. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J. Pharmacol. Exp. Ther. 262(3), 1195-1202 (1992).
13. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277(2), 805-816 (1996).
14. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J. Pharmacol. Exp. Ther. 283(2), 434-442 (1997).
15. Ishizaki T, Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13(Suppl. 3), 27-36 (1999).
16. Kupfer A, Preisig R: PharmaAogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26(6), 753-759 (1984).
17. Ishizaki T, Sohn DR. Kobayashi K et al.: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit. 16(2), 214-215 (1994).
18. Xiao ZS, Goldstein JA, Xie HG et al.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281(1), 604-609 (1997).
19. Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ: Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br. J. Clin. Pharmacol. 48(3), 402-408 (1999).
20. Marinac JS, Balian JD, Foxworth JW et al.: Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype. Clin. Pharmacol. Ther. 60(2), 138-144 (1996).
21. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 57(6), 656-661 (1995).
22. De Morais SM, Goldstein JA, Xie HG et al.: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin. Pharmacol. Ther. 58(4), 404-411 (1995).
23. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60(6), 661-666 (1996).
24. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6(6), 547-551 (1996).
25. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46(4), 594-598 (1994).
26. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269(22), 15419-15422 (1994).
27. Furuta T, Ohashi K, Kosuge K et al.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65(5), 552-561 (1999).
28. Furuta T, Ohashi K, Kobayashi K et al.: Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther. 66(3), 265-274 (1999).
29. Saitoh T, Fukushima Y, Otsuka H et al.: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 16(10), 1811-1817 (2002).
30. Shirai N, Furuta T, Moriyama Y et al.: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther. 15(12), 1929-1937 (2001).
31. Shirai N, Furuta T, Xiao F et al.: Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment. Pharmacol. Ther. 16(4), 837-846 (2002).
32. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 70(5), 484-492 (2001).
33. Nebel OT, Fornes MF, Castell DO: Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am. J. Dig. Dis. 21(11), 953-956 (1976).
34. Bardhan KD, Hawkey CJ, Long RG et al.: Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment. Pharmacol. Ther. 9(2), 145-151 (1995).
35. Bardhan KD: The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 9(Suppl. 1), 15-25 (1995).
36. Kirchgatterer A, Aschl G, Hinterreiter M, Stadler B, Knoflach P: [Current concepts in therapy of reflux disease.] Wien Med. Wochenschr. 151(11-12), 266-269 (2001).
37. Furuta T, Shirai N, Watanabe F et al.: Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 72(4), 453-460 (2002).
38. Kawamura M, Ohara S, Koike T et al.: The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol. Ther. 17(7), 965-973 (2003).
39. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 93(5), 763-767 (1998).
40. Adachi K, Fujishiro H, Katsube T et al.: Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J. Gastroenterol. Hepatol. 16(11), 1191-1196 (2001).
41. Klinkenberg-Knol EC, Meuwissen SG: Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment. Pharmacol. Ther. 4(5), 485-495 (1990).
42. Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: Clinical significance and correlation with esophageal acid exposure. Am. J. Gastroenterol. 98(3), 545-550 (2003).
43. Leite LP, Johnston BT, Just RJ, Castell DO: Persistent acid secretion during omeprazole therapy: A study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am. J. Gastroenterol. 91(8), 1527-1531 (1996).
44. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9(5), 539-549 (1999).
45. 2 blockers improve nocturnal gastric add control in GERD patients on proton pump inhibitors. Aliment. Pharmacol. Ther. 15(9), 1351-1356 (2001).
46. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 115(6), 1335-1339 (1998).
47. Kinoshita Y, Adachi K, Fujishiro H: Therapeutic approaches to reflux disease, focusing on acid secretion. J. Gastroenterol. 38(Suppl. 15), 13-19 (2003).
48. Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW: Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment. Pharmacol. Ther. 14(7), 887-892 (2000).
49. Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, CarlssIn E: Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol. Pathol. 16(2), 267-272 (1988).
50. Arnold R: Safety of proton pump inhibitors- an overview. Aliment. Pharmacol. Ther. 8(Suppl. 1), 65-70 (1994).
51. Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S: Long term omeprazole therapy for reflux esophagitis:fOllow-up in serum gastrin levels,EC cell hyperplasia and neoplasia. World J. Gastroenterol. 6(6), 789-792 (2000).
52. Sanduleanu S, Jonkers D, de Bruine A, Hameeteman W, Stockbrugger RW: Changes in gastric mucosa and luminal environment during acid-suppressive therapy: A review in depth. Dig. Liver Dis. 33(8), 707-719 (2001).
53. Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mardh S, Seensalu R: Omeprazole and CYP2E19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment. Pharmacol. Ther. 14(11), 1495-1502 (2000).
54. Bellou A, Aimone-Gastin I, De Korwin JD et al.: Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J. Intern. Med. 240(3), 161-164 (1996).
55. Sagar M, Janczewska I, Ljungdahl A, Bertilsson L, Seensalu R: Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment. Pharmacol. Ther. 13(4), 453-458 (1999).
56. Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SG: Review article: The development of atrophic gastritis-Helicobacter pylori and the effects of acid suppressive therapy. Aliment. Pharmacol. Ther. 9(4), 331-340 (1995).
57. Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 334(16), 1018-1022 (1996).
58. Correa P: Chronic gastritis as a cancer precursor. Scand. J. Gastroenterol. Suppl. 104, 131-136 (1984).
59. Correa P, Haenszel W, Cuello C et al.: Gastric precancerous process in a high risk population: Cross-sectional studies. Cancer Res. 50(15), 4731-4736 (1990).
60. Correa P, Haenszel W, Cuello C et al.: Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res. 50(15), 4737-4740 (1990).
61. Blaser MJ: Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 102(2), 720-727 (1992).
62. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV: Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102(1), 41-46 (1992).
63. Wotherspoon AC: Helicobacter pylori infection and gastric lymphoma. Br. Med. Bull. 54(1), 79-85 (1998).
64. Uemura N, Okamoto S, Yamamoto S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345(11), 784-789 (2001).
65. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC, Jr: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8(10), 888-889 (1989).
66. Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 43(Suppl. 1), S56-60 (1998).
67. Scott DR, Weeks D, Hong C, Postius S, Melchers K, Sachs G: The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 114(1), 58-70 (1998).
68. Goddard AF, Jessa MJ, Barrett DA et al.: Effect of omeprazole on die distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111(2), 358-367 (1996).
69. Midolo PD, Turnidge JD, Lambert JR, Bell JM: Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob. Agents Chemother. 40(6), 1531-1533 (1996).
70. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R eR al.: The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116(2), 248-253 (1999).
71. Furuta T, Ohashi K, Kamata T et al.: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129(12), 1027-1030 (1998).
72. Aoyama N, Tanigawara Y, Kita T et al.: Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J. Gastroenterol. 34(Suppl. 11), 80-83 (1999).
73. Yasuda S, Horai Y, Tomono Y et al.: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin. Pharmacol. Ther 58(2), 143-154 (1995).
74. Sakai T, Aoyama N, Kita T et al.: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res. 18(6), 721-727 (2001).
75. Ieiri I, Kishimoto Y, Okochi H et al.: Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur. J. Clin. Pharmacol. 57(6-7), 485-492 (2001).
76. Horai Y, Kimura M, Furuie H et al.: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther. 15(6), 793-803 (2001).
77. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 12(11), 1079-1089 (1998).
78. Adachi K, Katsube T, Kawamura A et al.: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther. 14(10), 1259-1266 (2000).
79. Kawai T, Oguma K, Kudou T: Comparison of dual therapy of rabeprazole plus amoxicillin and triple therapy for cure of Helicobacter pylori. Gastroenterology 120(Suppl. 1), A584 (2001).
80. Furuta T, Shirai N, Takashima M et al.: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11(4), 341-348 (2001).
81. Kawakami Y, Akahane T, Yamaguchi M et al.: In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 44(2), 458-461 (2000).
82. Tsuchiya M, Imamura L, Park JB, Kobashi K: Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol. Pharm. Bull. 18(8), 1053-1056 (1995).
83. Bell GD, Powell KU, Burridge SM et al.: Rapid eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 9(1), 41-46 (1995).
84. Lind T, Veldhuyzen van Zanten S, Unge P et al.: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I Study. Helicobacter 1(3), 138-144 (1996).
85. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333(15), 984-991 (1995).
86. Cederbrant G, Kahlmeter G, Ljungh A: Proposed mechanism for metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 29(2), 115-120 (1992).
87. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori: European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11(9), 777-781 (1992).
88. Peterson WL, Graham DY, Marshall B et al.: Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. Am. J. Gastroenterol. 88(11), 1860-1864 (1993).
89. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC: Cancer after exposure to metronidazole. Mayo Clin. Proc. 63(2), 147-153 (1988).
90. Alvan G, Bechtel P, Iselius L, Gundert-Remy U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39(6), 533-537 (1990).
91. Ferguson RJ, De Morais SM, Benhamou S et al.: A new genetic defect in human CYP2C19, mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284(1), 356-361 (1998).
92. Nakamura K, Goto F, Ray WA et al.: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38(4), 402-408 (1985).
93. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am. J. Gartroenterol. 93(3), 386-389 (1998).
94. Furuta T, Shirai N, Xiao F et al.: High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithoromycin and amoxicillin. Hepatogastroenterology 50(54), 2274-2278 (2003).
95. Andersson T, Miners JO, Veronese ME, Birkett DJ: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 37(6), 597-604 (1994).
96. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D: Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos. 25(5), 623-630 (1997).
97. Ushiama H, Echizen H, Nachi S, Ohnishi A:f Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin. Pharmacol. Ther. 72(1), 33-43 (2002).
98. Furuta T, Shirai N, Takashima M et al.: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69(3), 158-168 (2001).
99. Tanigawara Y, Aoyama N, Kita T et al.: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 66(5), 528-534 (1999).
100. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M: Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig. Liver Dis. 33(8), 671-675 (2001).
101. Versalovic J, Osato MS, Spakovsky K et al.: Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40(2), 283-286 (1997).
102. Stone GG, Shortridge D, Versalovic J. et al.: A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agents Chemother. 41(3), 712-714 (1997).
103. Menard A, Santos A, Megraud F, Oleastro M: PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob. Agents Chemother. 46(4), 1156-1157 (2002).
104. Bayerdorffer E, Miehlke S, Mannes GA et al.: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108(5), 1412-1417 (1995).
105. Miehlke S, Kirsch C, Ochsenkuehan T: High-dose omeprazole/amoxicillin therapy versus quadruple therapy for treatment of Helicobacter pylori resistant against both metroniadazol and clarithromycin: A prospective, randomised cross-over study. Gastroenterology 120(Suppl.), A120 (2001).